NeoGenomics Earnings Analysis: Q1 Recap
NeoGenomics Earnings Analysis: Q1 Recap
Revenue was up $19.02 million from the same period last year.The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM.
NeoGenomics（纳斯达克股票代码：NEO）的第一季度收益报告已于2024年4月30日星期二上午7点30分发布。
Here's what investors need to know about the latest announcement.
以下是投资者需要了解的有关最新公告的信息。
Earnings
收益
NeoGenomics beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05.
NeoGenomics的收益比预期高出60.0％，每股收益为-0.02美元，而估计为-0.05美元。
Revenue was up $19.02 million from the same period last year.
收入比去年同期增长了1,902万美元。
Analysis of Past Earnings
过去收益分析
Last quarter the company beat on EPS by $0.05 which was followed by a 12.0% increase in the share price the next day.
上个季度，该公司的每股收益高出0.05美元，随后第二天股价上涨了12.0％。
Here's a look at NeoGenomics's past performance:
以下是新基因组学过去的表现：
| Quarter | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|
| EPS Estimate | -0.05 | -0.02 | -0.08 | -0.11 | -0.15 |
| EPS Actual | -0.02 | 0.03 | 0 | -0.05 | -0.09 |
| Revenue Estimate | 149.89M | 152.54M | 142.00M | 137.42M | 126.39M |
| Revenue Actual | 156.24M | 155.55M | 151.95M | 146.92M | 137.22M |
| 季度 | 2024 年第一季度 | 2023 年第四季度 | 2023 年第三季度 | 2023 年第二季度 | 2023年第一季度 |
|---|---|---|---|---|---|
| 每股收益估算 | -0.05 | -0.02 | -0.08 | -0.11 | -0.15 |
| 实际每股收益 | -0.02 | 0.03 | 0 | -0.05 | -0.09 |
| 收入估算 | 149.89 亿 | 152.54 亿 | 142.00 亿 | 137.42 亿 | 126.39 亿 |
| 实际收入 | 156.24 亿 | 155.55 亿 | 151.95 亿 | 146.92 亿 | 137.22 亿 |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
新投资者应注意，有时对股票价格影响最大的不是收益超过或失败，而是指导方针（或预测）。
Guidance
指导
NeoGenomics management provided guidance for FY 2024, expecting earnings between $0.0 and $0.04 per share.
NeoGenomics管理层为2024财年提供了指导，预计每股收益在0.0美元至0.04美元之间。
Recent Earnings Releases from Competitors
竞争对手发布的最新财报
With NeoGenomics's earnings data in hand, it's essential to compare its metrics to those of similar companies, including BrightSpring Health, Guardant Health, and R1 RCM.
有了NeoGenomics的收益数据，将其指标与包括BrightSpring Health、Guardant Health和R1 RCM在内的类似公司的指标进行比较至关重要。
- BrightSpring Health's earnings on May 02, 2024 exceeded market projections, revealing an EPS of $0.12 compared to the estimated EPS of $0.07, resulting in a 71.43% increase.
- The latest earnings announcement from Guardant Health on May 09, 2024 exceeded expectations, with an actual EPS of $-0.46 compared to the market's estimate of $-0.85, resulting in a 45.88% increase.
- On May 08, 2024, R1 RCM unveiled earnings that were below market expectations, with an actual EPS of $-0.08 compared to an estimated EPS of $-0.01, resulting in a -700.0% decrease.
- BrightSpring Health在2024年5月2日的收益超出了市场预期，显示每股收益为0.12美元，而估计的每股收益为0.07美元，增长了71.43％。
- Guardant Health于2024年5月9日发布的最新收益超出了预期，实际每股收益为-0.46美元，而市场预期的为-0.85美元，增长了45.88％。
- 2024年5月8日，R1 RCM公布的收益低于市场预期，实际每股收益为-0.08美元，而估计的每股收益为-0.01美元，下降了-700.0％。
Competitors Quarterly Earnings and Stock Performance Analysis
竞争对手的季度收益和股票表现分析
This analysis provides insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with the corresponding stock prices at the close of the announcement day and the open of the following trading day.
该分析提供了对市场对主要竞争对手最新财报的反应的见解。它重点介绍了每家公司的预期和已公布的每股收益（EPS），以及公告日收盘时和下一个交易日开盘时的相应股价。
| Company Name | Date | EPS Expected | EPS Announced | EPS Change Percent | Stock Price At Close | Stock Price at Next Day Open | Price Change Percent |
|---|---|---|---|---|---|---|---|
| NeoGenomics | April 30, 2024 | -0.05 | -0.0260.0% | $13.92 | $14.0 | 0.57% | |
| BrightSpring Health | May 02, 2024 | 0.07 | 0.1271.43% | $11.06 | $11.27 | 1.9% | |
| Guardant Health | May 09, 2024 | -0.85 | -0.4645.88% | $19.44 | $21.84 | 12.35% | |
| R1 RCM | May 08, 2024 | -0.01 | -0.08-700.0% | $12.84 | $12.67 | -1.32% |
| 公司名 | 日期 | 预期每股收益 | 每股收益公布 | 每股收益变化百分比 | 收盘时股价 | 次日开盘时的股价 | 价格变动百分比 |
|---|---|---|---|---|---|---|---|
| 新基因组学 | 2024年4月30日 | -0.05 | -0.0260.0% | 13.92 美元 | 14.0 美元 | 0.57% | |
| 光明春日健康 | 2024 年 5 月 2 日 | 0.07 | 0.1271.43% | 11.06 美元 | 11.27 美元 | 1.9% | |
| 守护者生命值 | 2024年5月9日 | -0.85 | -0.4645.88% | 19.44 美元 | 21.84 美元 | 12.35% | |
| R1 RCM | 2024年5月8日 | -0.01 | -0.08-700.0% | 12.84 美元 | 12.67 美元 | -1.32% |
Analyzing Peer Revenue Discrepancy: Estimated vs. Announced
分析同行收入差异：估计值与公布收入差异
The comparison table below presents estimated and announced revenue figures for NeoGenomics's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context for understanding their financial standing within the industry.
下表显示了NeoGenomics同行的估计和公布的收入数据。这种比较可以深入了解这些公司的收入表现，为了解其在行业中的财务状况提供了宝贵的背景信息。
| Company Name | Estimated Revenue | Announced Revenue | Revenue Surprise Percentage |
|---|---|---|---|
| NeoGenomics | 149.89M | 156.24M | 4.24% |
| BrightSpring Health | 2.31B | 2.58B | 11.56% |
| Guardant Health | 150.67M | 168.49M | 11.83% |
| R1 RCM | 611.93M | 603.90M | -1.31% |
| 公司名 | 预计收入 | 公布的收入 | 收入意外百分比 |
|---|---|---|---|
| 新基因组学 | 149.89 亿 | 156.24 亿 | 4.24% |
| 光明春日健康 | 2.31B | 2.58B | 11.56% |
| 守护者生命值 | 150.67 亿 | 168.49 亿 | 11.83% |
| R1 RCM | 611.93 亿 | 603.90 亿 | -1.31% |
To track all earnings releases for NeoGenomics visit their earnings calendar here.
要追踪NeoGenomics的所有财报，请在此处访问他们的财报日历。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自动内容引擎生成，并由编辑审阅。